Kiniksa Pharmaceuticals
KNSA
96 hedge funds and large institutions have $306M invested in Kiniksa Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 30 reducing their positions, and 20 closing their positions.
38% more call options, than puts
Call options by funds: $2.44M | Put options by funds: $1.77M
20% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 30
3.41% more ownership
Funds ownership: 86.85% → 90.27% (+3.4%)
7% less funds holding
Funds holding: 103 → 96 (-7)
12% less capital invested
Capital invested by funds: $346M → $306M (-$40.4M)
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.16M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.3M |
| 3 |
Millennium Management
New York
|
+$4.88M |
| 4 |
LPC
Lion Point Capital
New York
|
+$4.5M |
| 5 |
Goldman Sachs
New York
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.51M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.87M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.81M |
| 4 |
Renaissance Technologies
New York
|
-$1.53M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.05M |
KNSA Hedge Fund Activity: Q1 2022 in Review
96 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2022, worth a combined $306M — down 12% from $346M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KNSA and 13 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 36 added.
The largest buyer was Great Point Partners, adding an estimated $6.16M. The largest seller was State Street, cutting an estimated $9.51M.
- 96 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2022, down from 103 in Q4 2021.
- Funds reported $306M of Kiniksa Pharmaceuticals stock for Q1 2022, down 12% quarter-over-quarter.
- 13 funds opened new Kiniksa Pharmaceuticals positions in Q1 2022 and 20 closed out, a net change of -7 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2022 was Great Point Partners, an estimated $6.16M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2022 was State Street, an estimated $9.51M sold.
Based on aggregated 13F filings for Q1 2022.